Cytotoxicity of graphene oxide and graphene oxide loaded with doxorubicin on human multiple myeloma cells

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 1413-1421

  Wu, Shaoling ^a   Zhao, Xindong ^b   Cui, Zhongguang ^a   Zhao, Chunting ^a   Wang, Yuzhen ^a   Du, Li ^a   Li, Yanhui ^a,c  

^a QINGDAO UNIVERSITY   (China)

^b QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^c NONE   (China)

Author keywords

CCK 8; Cell apoptosis; Cell cycle; Doxorubicin; Graphene oxide; Human multiple myeloma cell

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; DOXORUBICIN LOADED GRAPHENE OXIDE; GRAPHENE OXIDE; NANOCARRIER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL;

CCK-8; CELL APOPTOSIS; CELL CYCLE; DOXORUBICIN; GRAPHENE OXIDE; HUMAN MULTIPLE MYELOMA CELL;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DIFFUSION; DOXORUBICIN; GRAPHITE; HUMANS; MULTIPLE MYELOMA; NANOCAPSULES; OXIDES; TREATMENT OUTCOME;

EID: 84897865492     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S57946     Document Type: Article

References (33)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351: 1860-1873.
2. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111(5):2521-2526.
3. Michel A, Jean-Luc H, Anne-Marie S, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
4. Anderson Kenneth C. Multiple myeloma: how far have we come? Mayo Clin Proc. 2003;78(1):15-17.
5. Geneviève AS, Danielle LG. Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie. 1984;66(5):333-352.
6. Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet. 1988;15(1):15-31.
7. Tulubas F, Gurel A, Oran M, Topcu B, Caglar V, Uygur E. The protective effects of ω-3 fatty acids on doxorubicin-induced hepatotoxicity and nephrotoxicity in rats. Toxicol Ind Health. Epub March 19, 2013.
8. El-Sheikh AA, Morsy MA, Mahmoud MM, Rifaai RA, Abdelrahman AM. Effect of coenzyme-q10 on doxorubicin-induced nephrotoxicity in rats. Adv Pharmacol Sci. 2012;2012:981461.
9. Lyseng-Williamson KA, Duggan ST, Keating GM. Pegylated liposomal Doxorubicin: a guide to its use in various malignancies. BioDrugs. 2013;27(5):533-540.
10. Khan MFS, Alexander AB. Thermal properties of graphene and multilayer graphene: applications in thermal interface materials. Solid State Commun. 2012;152(15):1331-1340.
11. 2/graphene nanocomposite as an anode material for lithium-ion batteries. Electrochim Acta. 2011;56(12):4532-4539.
12. Gao Y, Li Y, Zhang L, et al. Adsorption and removal of tetracycline antibiotics from aqueous solution by graphene oxide. J Colloid Interf Sci. 2012;368(1):540-546.
13. Premkumar T, Geckeler KE. Graphene-DNA hybrid materials: assembly, applications, and prospects. Prog Polym Sci. 2012;37(4):515-529.
14. Depan D, Shah J, Misra RDK. Controlled release of drug from folate-decorated and graphene mediated drug delivery system: synthesis, loading efficiency, and drug release response. Mater Sci Eng C. 2011;31(7):1305-1312.
15. Liu Z, Robinson JT, Tabakman SM, Yang K, Dai H. Carbon materials for drug delivery and cancer therapy. Mater Today. 2011;14(7-8): 316-323.
16. Markovic ZM, Harhaji-Trajkovic LM, Todorovic-Markovic BM, et al. In vitro comparison of the photothermal anticancer activity of graphene nanoparticles and carbon nanotubes. Biomaterials. 2011;32(4): 1121-1129.
17. Wang Z, Gao Y, Xia J, Zhang F, Xia Y, Li Y. Synthesis and characterization of glycyrrhizin-decorated graphene oxide for hepatocyte-targeted delivery. C R Chim. 2012;15(8):708-713.
18. Wu S, Zhao X, Li Y, et al. Adsorption properties of doxorubicin hydrochloride onto graphene oxide: equilibrium, kinetic and thermodynamic studies. Materials. 2013;6(5):2026-2042.
19. Zhao GX, Li JX, Wang XK. Kinetic and thermodynamic study of 1-naphthol adsorption from aqueous solution to sulfonated graphene nanosheets. Chem Eng J. 2011;173(1):185-190.
20. Pan B, Xing B. Adsorption mechanisms of organic chemicals on carbon nanotubes. Environ Sci Technol. 2008;42(24):9005-9013.
21. Pan B, Xing B. Adsorption of phenolic compounds by carbon nanotubes: role of aromaticity and substitution of hydroxyl groups. Environ Sci Technol. 2008;42(19):7254-7259.
22. Li Y, Liu Y, Fu Y, et al. The triggering of apoptosis in macrophages by pristine graphene through the MAPK and TGF-beta signaling pathways. Biomaterials. 2012;33(2):402-411.
23. Zhou H, Zhao K, Li W, et al. The interactions between pristine graphene and macrophages and the production of cytokines/chemokines via TLR- and NF-κB-related signaling pathways. Biomaterials. 2012;33(29): 6933-6942.
24. Akhavan O, Ghaderi E, Akhavan A. Size-dependent genotoxicity of graphene nanoplatelets in human stem cells. Biomaterials. 2012;33(32): 8017-8025.
25. Vallabani NV, Mittal S, Shukla RK, et al. Toxicity of graphene in normal lung cells (BEAS-2B). J Biomed Nanotechnol. 2011;7(1):106-107.
26. Chang Y, Yang ST, Liu JH, et al. In vitro toxicity evaluation of graphene oxide on A549 cells. Toxicol Lett. 2011;200(3):201-210.
27. Wojtoniszak M, Chen X, Kalenczuk RJ, et al. Synthesis, dispersion, and cytocompatibility of graphene oxide and reduced graphene oxide. Colloid Surface B. 2012;89(1):79-85.
28. Liu JH, Yang ST, Wang H, et al. Effect of size and dose on the biodistribution of graphene oxide in mice. Nanomedicine. 2012;7(12): 1801-1812.
29. Yang K, Wan J, Zhang S, Zhang Y, Lee ST, Liu Z. In vivo pharmacokinetics, long-term biodistribution, and toxicology of PEGylated graphene in mice. ACS Nano. 2011;5(1):516-522.
30. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42(5):419-436.
31. Ni Y, Zhang F, Kokot S. Graphene oxide as a nanocarrier for loading and delivery of medicinal drugs and as a biosensor for detection of serum albumin. Analytica Chimica Acta. 2013;969(1):40-48.
32. Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. Small. 2008;4(1):26-49.
33. Lammel T, Boisseaux P, Fernández-Cruz M, Navas JM. Internalization and cytotoxicity of graphene oxide and carboxyl graphene nanoplatelets in the human hepatocellular carcinoma cell line HepG 2. Part Fibre Toxicol. 2013;10:27.